Madrigal Pharmaceuticals is developing novel, high-quality small-molecule drugs addressing major unmet needs in cardiovascular and metabolic diseases. The Company is targeting treatment of both niche and prevalent indications, including diabetes, dyslipidemia and cardiovascular disease. Madrigal’s lead drug candidate is MGL-3196, a Phase 2 ready orally administered liver-directed thyroid hormone receptor-ß (THR-ß) agonist. In Madrigal’s 14-day multiple dose Phase 1 study in healthy volunteers with mildly elevated LDL cholesterol, MGL-3196 demonstrated safety and excellent tolerability at all doses tested. In the multiple dose study, MGL-3196 demonstrated proof-of-concept for lipid lowering including dose-dependent, highly significant, up to 30% lowering of LDL cholesterol and non-HDL cholesterol, and a strong trend of up to 60% triglyceride lowering. These results suggest that MGL-3196 has a unique lipid lowering profile as compared with other agents and a potential to significantly reduce cholesterol, triglycerides and liver triglycerides. Elevated cholesterol, triglycerides and fatty liver are an underlying cause of many metabolic and cardiovascular diseases, which, themselves, are associated with increased mortality.

Madrigal is also developing a Diacylglycerol Acyltransferase 1 (DGAT1) inhibitor for diabetes, a target with potential additional application in weight control and dyslipidemia.

EVENTS

245th ACS National Meeting and Exposition

280 – Discovery and development of MGL-3196, a liver-directed thyroid hormone beta agonist for the treatment of hypercholesterolemia/dyslipidemia and hypertriglyceridemia
April 10, 2013, 4:20pm | First Time Disclosures Session, Morial Convention Center, Room R02-R04 | New Orleans, Louisiana

GTC Diabetes Summit 2013

Novel Treatment for Diabetic Dyslipidemia: Rapid and Robust Lowering of LDL, Non-HDL Cholesterol, Apolipoprotein B and Triglycerides after Multiple Doses of MGL-3196, Liver-Directed Thyroid Hormone Receptor-ß Agonist in Phase 1 Studies
April 29-30, 2013 | Boston, MA

See more Events


NEWS

Madrigal Pharmaceuticals Discloses the Structure and Enhanced Safety Properties of MGL-3196 at the 245th American Chemical Society National Meeting and Exposition

April 10, 2013
download

Madrigal Pharmaceuticals Announces Results From MGL-3196 Multiple Dose Study at the American Heart Association 2012 Scientific Sessions

Nov 6, 2012
download

See more News